Lundbeck
HLUN-B.CO
#2099
Rank
NZ$16.02 B
Marketcap
NZ$16.15
Share price
-2.27%
Change (1 day)
32.55%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Earnings for Lundbeck (HLUN-B.CO)

Earnings in 2026 (TTM): NZ$1.45 Billion

According to Lundbeck's latest financial reports the company's current earnings are NZ$4.03 Billion. In 2025 the company made an earning of NZ$1.37 Billion, an increase over its 2024 earnings that were of NZ$1.00 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Lundbeck from 2009 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.45 B5.57%
2025 NZ$1.37 B36.57%
2024 NZ$1.00 B25.74%
2023 NZ$0.80 B21.77%
2022 NZ$0.65 B31.57%
2021 NZ$0.50 B-4.61%
2020 NZ$0.52 B-45.06%
2019 NZ$0.95 B-34.04%
2018 NZ$1.44 B12.83%
2017 NZ$1.28 B93.99%
2016 NZ$0.66 B-137.28%
2015 -NZ$1.78 Billion-1246.24%
2014 NZ$0.15 B-72.36%
2013 NZ$0.55 B4.38%
2012 NZ$0.53 B-55.18%
2011 NZ$1.19 B5.65%
2010 NZ$1.13 B-5.9%
2009 NZ$1.20 B